GALLIUM: What the Lymphoma Trial Found

The disease GALLIUM was testing in

Follicular lymphoma is not one of the fast cancers. NCI calls it the most common indolent, meaning slow-growing, type of non-Hodgkin lymphoma. It starts in B lymphocytes, a kind of white blood cell, affects the lymph nodes, and can reach the bone marrow or spleen. Most people are 50 or older at diagnosis.

NCI adds something unusual: follicular lymphoma may go away without treatment, and some people are simply watched closely instead of treated.

When treatment is needed, the backbone for two decades has been rituximab, an antibody that latches onto a protein called CD20 on the surface of B cells and marks them for destruction, given alongside chemotherapy.

The question

Obinutuzumab is a newer anti-CD20 antibody. It is described as glycoengineered and type II, meaning its sugar coating and its binding behavior were deliberately altered to make immune cells destroy the tagged B cells more efficiently.

The question GALLIUM asked was simple. In people receiving their first treatment for advanced follicular lymphoma, does swapping obinutuzumab for rituximab do better?

How it was run

A total of 1,202 people with previously untreated advanced-stage follicular lymphoma were randomized, 601 to each group. Everyone received induction treatment with chemotherapy plus one of the two antibodies. Those who responded went on to maintenance treatment for up to two years with the same antibody.

The measure that counted was progression-free survival: the time before the lymphoma grew again or the person died. The trial is registered as NCT01332968. Our guide to clinical trial phases explains how a phase 3 comparison like this is structured.

What the interim analysis showed

At a planned interim look, after a median follow-up of 34.5 months, the estimated three-year progression-free survival was 80.0% in the obinutuzumab group and 73.3% in the rituximab group.

That is about seven percentage points. The hazard ratio was 0.66, with a confidence interval of 0.51 to 0.85 and P equal to 0.001, meaning roughly a third lower risk of progression, relapse or death at any given moment.

Response rates were essentially the same: 88.5% against 86.9%. The advantage was in how long the response held, not in whether it happened.

What it cost

Serious side effects, graded 3 to 5, occurred in 74.6% of the obinutuzumab group against 67.8% of the rituximab group. Serious adverse events overall were 46.1% against 39.9%.

The most common problems were infusion-related reactions, which happened in 59.3% of people receiving obinutuzumab and 48.9% of those receiving rituximab. Nausea and neutropenia, meaning low counts of the white cells that fight bacteria, were common in both groups.

Deaths from side effects were similar, at 4.0% and 3.4%. Overall, 35 people in the obinutuzumab group and 46 in the rituximab group died during the study.

Why rituximab did not disappear

A positive trial does not automatically end a debate, and this one is a good illustration.

Progression-free survival improved. Overall survival did not show a benefit at this analysis. Toxicity was higher. Follicular lymphoma is slow, so people live a long time with it and often go through several lines of treatment, which makes the question of which drug to use first genuinely open.

Many centers still start with rituximab and hold obinutuzumab in reserve. Both are reasonable readings of the same data.

Where lymphoma stands

SEER carries American Cancer Society projections of 79,320 new US non-Hodgkin lymphoma diagnoses and 19,970 deaths in 2026. NCI's own SEER measurement of five-year relative survival, for cases diagnosed in 2016 to 2022, is 74.3%.

That figure covers every type of non-Hodgkin lymphoma together, from slow follicular lymphoma to fast aggressive subtypes, so it should be read as a very rough average. It is a group statistic over past years and says nothing about any individual. Our page on lymphoma explains the main types.

When to get checked

NCI lists these signs of non-Hodgkin lymphoma. Any of them lasting more than two to three weeks warrants an appointment:

• Swelling in the lymph nodes of the neck, underarm, groin or abdomen, usually painless
• Fever with no known cause
• Drenching night sweats, the kind that soak bedding
• Feeling very tired
• Weight loss with no known cause
• Skin rash or itchy skin
• Pain in the chest, abdomen or bones with no known cause

NCI notes that fever, drenching night sweats and weight loss occurring together have a specific name: B symptoms. They matter to staging and to the treatment decision, so mention them together rather than separately.

What this does not mean

• No overall survival benefit was demonstrated. The improvement was in time before the lymphoma progressed.
• Serious side effects were more frequent with obinutuzumab, including more infusion reactions.
• This was a planned interim analysis at a median of 34.5 months. Follicular lymphoma is a slow disease and three years is short against its natural history.
• Each site chose its own chemotherapy backbone, which introduces variation and later raised concerns about excess deaths with some bendamustine combinations.
• Trial participants meet specific entry criteria, so results may not carry over to everyone with this diagnosis.

Sources

• New England Journal of Medicine (record via PubMed), Obinutuzumab for the First-Line Treatment of Follicular Lymphoma (GALLIUM) — https://pubmed.ncbi.nlm.nih.gov/28976863/
• ClinicalTrials.gov, NCT01332968 (GALLIUM) — https://clinicaltrials.gov/study/NCT01332968
• NCI PDQ, Adult Non-Hodgkin Lymphoma Treatment (Patient Version) — https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
• SEER Cancer Stat Facts, Non-Hodgkin Lymphoma — https://seer.cancer.gov/statfacts/html/nhl.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.